WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464824
CAS#: 923-37-5
Description: Ureidosuccinic acid is an intermediate in the de novo pyrimidine nucleotide biosynthesis pathway. It is formed from aspartate and carbamoyl phosphate via aspartate carbamoyltransferase. Ureidosuccinic acid (350 mg/kg) inhibits antitumor activity and toxicity induced by the aspartate carbamoyltransferase inhibitor N-phosphonacetyl-L-aspartate (PALA) in a murine Lewis lung carcinoma model.
Hodoodo Cat#: H464824
Name: Ureidosuccinic Acid
CAS#: 923-37-5
Chemical Formula: C5H8N2O5
Exact Mass: 176.04
Molecular Weight: 176.130
Elemental Analysis: C, 34.10; H, 4.58; N, 15.91; O, 45.42
Synonym: Ureidosuccinic Acid; Ureidosuccinic-Acid; N-Carbamoylaspartic Acid; N Carbamoylaspartic Acid; N-Carbamoyl-DL-Aspartic Acid; NSC 120033; NSC120033; NSC-120033;
IUPAC/Chemical Name: N-Carbamoyl-DL-aspartic acid
InChi Key: HLKXYZVTANABHZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)
SMILES Code: O=C(O)CC(C(O)=O)NC(N)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMF | 1.0 | 2.85 | |
DMSO | 1.0 | 2.85 | |
PBS (pH 7.2) | 1.0 | 2.85 |
The following data is based on the product molecular weight 176.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Shen C, Sun Z, Chen D, Su X, Jiang J, Li G, Lin B, Yan J. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. OMICS. 2015 Jan;19(1):1-11. doi: 10.1089/omi.2014.0116. PMID: 25562196; PMCID: PMC4281851.
2: Schlumpberger M, Prusiner SB, Herskowitz I. Induction of distinct [URE3] yeast prion strains. Mol Cell Biol. 2001 Oct;21(20):7035-46. doi: 10.1128/MCB.21.20.7035-7046.2001. PMID: 11564886; PMCID: PMC99879.